Baker Avenue Asset Management LP Has $12.25 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Baker Avenue Asset Management LP increased its stake in Eli Lilly and Company (NYSE:LLY) by 0.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,871 shares of the company’s stock after acquiring an additional 62 shares during the quarter. Baker Avenue Asset Management LP’s holdings in Eli Lilly and Company were worth $12,253,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company’s stock worth $57,320,226,000 after buying an additional 475,530 shares in the last quarter. Geode Capital Management LLC boosted its stake in Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock worth $13,389,651,000 after acquiring an additional 291,875 shares in the last quarter. Wellington Management Group LLP grew its holdings in Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares during the period. Norges Bank bought a new stake in Eli Lilly and Company in the fourth quarter valued at $8,407,908,000. Finally, Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 16.1% during the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company’s stock valued at $8,304,811,000 after purchasing an additional 1,493,673 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LLY shares. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price for the company. Citigroup lowered their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Finally, Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,002.80.

Eli Lilly and Company Trading Up 3.9 %

NYSE LLY opened at $825.10 on Friday. The business’s fifty day moving average is $825.36 and its 200-day moving average is $815.67. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $782.34 billion, a price-to-earnings ratio of 70.46, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the previous year, the firm earned $2.58 earnings per share. The firm’s revenue was up 45.2% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.